Menu
 
Research menu
Jump to menu

Publications:  Dr Monica Calado Marta

Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, Mathews J, Lambourne J et al.(2020). Protecting people with multiple sclerosis through vaccination. Pract Neurol
10.1136/practneurol-2020-002527
Baker D, Pryce G, James LK, Marta M, Schmierer K(2020). The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis. Multiple Sclerosis and Related Disorders Article 102279, 102279-102279.
10.1016/j.msard.2020.102279
Smets I, Reyes S, Carrillo-Loza K, Mateo-Casas M, Bianchi L, Holden D, Ammoscato F, Turner B et al. (2020). CSF Neurofilament Light Chain for guiding individual treatment decisions in multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. vol. 27, 475-476.
Reyes S, Suarez S, Allen-Philbey K, Yildiz Ö, Mathews J, Anjorin G, Edwards F, Jain C et al.(2020). Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis. Multiple Sclerosis and Related Disorders vol. 41,
10.1016/j.msard.2020.102024
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63180
Krysko KM, Graves JS, Dobson R, Altintas A, Amato MP, Bernard J, Bonavita S, Bove R et al.(2020). Sex effects across the lifespan in women with multiple sclerosis. Therapeutic Advances in Neurological Disorders vol. 13,
10.1177/1756286420936166
Reyes S, Allen-Philbey K, Suarez S, Yildiz O, Turner B, Gnanapavan S, Schmierer K, Marta M et al. (2019). DOES SOCIOECONOMIC STATUS IMPACT ON THE PRESCRIPTION OF DISEASE-MODIFYING TREATMENTS IN PEOPLE WITH MULTIPLE SCLEROSIS?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 90, E58-E58.
10.1136/jnnp-2019-ABN-2.164
De Trane S, Allen-Philbey K, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. (2019). Cladribine at all stages of MS: two-year follow-up in 154 patients. MULTIPLE SCLEROSIS JOURNAL. vol. 25, 519-520.
Reyes S, Carrillo-Loza K, Mateo M, Bianchi L, Holden D, Ammoscato F, Marta M, Turner B et al. (2019). Evidence of the utility of CSF neurofilament light chain measurements in people with MS in clinical practice. MULTIPLE SCLEROSIS JOURNAL. vol. 25, 854-854.
Bianchi L, Baker D, Giovannoni G, Marta M (2019). Neurofilament light chain levels in cerebrospinal fluid and serum of a longitudinal cohort of people with multiple sclerosis on disease modifying drugs. MULTIPLE SCLEROSIS JOURNAL. vol. 25, 734-735.
Marta M, Bianchi L, Lieberman D, Ciccarelli O, Collorone S, Kapoor R, Chataway J, Schmierer K et al. (2019). Oxcarbazepine as a neuroprotective agent in MS: a phase IIa trial (PROXIMUS). MULTIPLE SCLEROSIS JOURNAL. vol. 25, 91-91.
Lieberman DR, Giovannoni G, Cafferty F, Bianchi L, Gnanapavan S, Marta M, Altmann DR, Kapoor R (2019). Seamless phase II-III adaptive trial design elements for progressive MS: Neurofilament light chain (phase II/interim endpoint), phase III endpoints and patient populations. MULTIPLE SCLEROSIS JOURNAL. vol. 25, 600-600.
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al. (2019). Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in > 200 patients. NEUROLOGY. vol. 92,
Carrillo-Loza K, Reyes S, Bianchi L, Holden D, Espasandin M, Ammoscato F, Turner B, Schmierer K et al. (2019). Real life Evidence for CSF Neurofilaments Light Chain in Clinical Practice. NEUROLOGY. vol. 92,
DOBSON R(2019). Visibility and representation of women in multiple sclerosis research. Neurology
10.1212/WNL.0000000000007276
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56468
Marta M(2019). No evidence of disease activity in people with multiple sclerosis. Eur J Neurol vol. 26, (1) 1-2.
10.1111/ene.13771
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57669
Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al.(2019). Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. Multiple Sclerosis and Related Disorders vol. 27, 247-253.
10.1016/j.msard.2018.11.001
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55054
Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G(2018). Inclusion criteria used in trials of people with progressive multiple sclerosis. Mult Scler1352458518803769-1352458518803769.
10.1177/1352458518803769
https://qmro.qmul.ac.uk/xmlui/handle/123456789/49361
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner BP et al. (2018). Cladribine personalised dosing in people with MS (n > 200) - four years experience in clinical care.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65488
Gold J, Marta M, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al.(2018). A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. Multiple Sclerosis and Related Disorders vol. 24, 123-128.
10.1016/j.msard.2018.06.002
https://qmro.qmul.ac.uk/xmlui/handle/123456789/42250
Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al.(2018). Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. Multiple Sclerosis Journal - Experimental, Translational and Clinical vol. 4, (2) 2055217318783767-2055217318783767.
10.1177/2055217318783767
https://qmro.qmul.ac.uk/xmlui/handle/123456789/43785
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al.(2018). Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology vol. 154, (2) 253-260.
10.1111/imm.12879
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31849
Mao Z, Alvarez-Gonzalez C, Yildiz O, Allen-Philbey K, Turner B, Gnananpavan S, Marta M, Mathews J et al. (2018). Personalised dosing of cladribine for people with multiple sclerosis. NEUROLOGY. vol. 90,
Reyes S, Allen-Philbey K, Suarez S, Yildiz O, Turner B, Gnanapavan S, Schmierer K, Marta M et al. (2018). The Impact of Socioeconomic Status on Treatment Choice in Patients with Multiple Sclerosis. NEUROLOGY. vol. 90,
Rackstraw S, Marta M (2018). Clinical presentation and treatment of patients with neurosymptomatic HIV cerebrospinal fluid escape. HIV MEDICINE. vol. 19, S74-S75.
Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K(2017). Disease modification in advanced MS: Focus on upper limb function. Multiple Sclerosis vol. 23, (14) 1956-1957.
10.1177/1352458517717811
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25093
Schmierer K, Marta M, Pryce G, Giovannoni G, Baker D (2017). MEMORY B CELLS ARE KEY FOR IMMUNOTHERAPY IN MULTIPLE SCLEROSIS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 88, A52-A52.
10.1136/jnnp-2017-ABN.179
Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Gnanapavan S, Marta M, Baker D et al. (2017). PERSONALISED DOSING OF CLADRIBINE TO TREAT MULTIPLE SCLEROSIS. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 88, A47-A48.
10.1136/jnnp-2017-ABN.164
Dubuisson N, Bauer A, Marta M, Gnanapavan S, Turner B, Baker D, Giovannoni G, Schmierer K et al. (2017). VALIDATION OF AN ENVIRONMENTALLY-FRIENDLY AND AFFORDABLE CARDBOARD 9-HOLE PEG TEST. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 88, A44-A45.
10.1136/jnnp-2017-ABN.154
Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Turner B, Gnanapavan S, Marta M, Mathews J, Giovannoni G et al. (2017). Cladribine personalised dosing to treat multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. vol. 23, 609-609.
Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Schmierer K, Giovannoni G (2017). Identification of main inclusion criteria of chronic progressive multiple sclerosis clinical trials: a review. MULTIPLE SCLEROSIS JOURNAL. vol. 23, 939-940.
Dubuisson N, Bauer A, Buckley M, Gilbert R, Paterson A, Marta M, Gnanapavan S, Turner B et al.(2017). Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. Multiple Sclerosis and Related Disorders vol. 17, 172-176.
10.1016/j.msard.2017.08.002
https://qmro.qmul.ac.uk/xmlui/handle/123456789/29763
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K(2017). Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine vol. 16, 41-50.
10.1016/j.ebiom.2017.01.042
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23134
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Baker D, Gnanapavan S, Marta M, Giovannoni G et al. (2016). TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 87,
10.1136/jnnp-2016-315106.121
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55055
Thomson A, Giovannoni G, Marta M, Gnanpavan S, Turner B, Baker D, Schmierer K (2016). Importance of upper limb function in advanced multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 676-676.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25226
Gold J, Marta MC, Meier UC, Christensen T, Miller D, Altmann D, Holden D, Bianchi L et al. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 188-189.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25994
Marta M, MacManus D, Yousry T, Miller D, Altmann DR, Meier UC, Christensen T, Maruszak H et al. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22, 188-188.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25993
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Espasandin M, Turner BP, Gnanapavan S, Marta M, Giovannoni G et al. (2016). Treating multiple sclerosis with generic cladribine. MULTIPLE SCLEROSIS JOURNAL. Conference: MSLondon (ACTRIMS/ECTRIMS) vol. 22, 604-605.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25052
Samoes R, Rackstraw S, Marta M (2016). HIV-PML: remember to test. EUROPEAN JOURNAL OF NEUROLOGY. vol. 23, 795-795.
Williams T, Marta M, Giovannoni G(2016). IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension. Practical Neurology vol. 16, (3) 235-239.
10.1136/practneurol-2015-001275
Giovannoni G, Marta M, Davis A, Turner B, Gnanapavan S, Schmierer K(2016). Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Practical Neurologypractneurol-2015-001-practneurol-2015-001.
10.1136/practneurol-2015-001355
https://qmro.qmul.ac.uk/xmlui/handle/123456789/14950
Martins J, Santos E, Salgado P, Maia L, Dias D, Marta M, França M(2016). Recurrent cerebrospinal fluid escape in an HIV-1-infected patient receiving antiretroviral therapy. AIDS vol. 30, (7) 1143-1144.
10.1097/QAD.0000000000001037
https://qmro.qmul.ac.uk/xmlui/handle/123456789/14908
Tong CYW, Costelloe S, Hubb J, Mullen J, O'Shea S, Marta M, Kulasegaram R, Rackstraw S(2015). Deep Sequencing of HIV-1 in Cerebrospinal Fluid. Clin Infect Dis vol. 61, (6) 1022-1025.
10.1093/cid/civ417
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15419
Gold J, Giovannoni G, Marta MC, Meier U, Miller D, Christensen T, Maruszak H, Holden D et al. (2015). Pilot baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study. MULTIPLE SCLEROSIS JOURNAL. vol. 21, 162-162.
Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M(2015). Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. Multiple Sclerosis and Related Disorders vol. 4, (4) 329-333.
10.1016/j.msard.2015.04.006
https://qmro.qmul.ac.uk/xmlui/handle/123456789/8421
Marta M, Santos E, Coutinho E, Silva AM, Correia J, Vasconcelos C, Giovannoni G(2015). The role of infections in Behçet disease and neuro-Behçet syndrome. Autoimmun Rev vol. 14, (7) 609-615.
10.1016/j.autrev.2015.02.009
https://qmro.qmul.ac.uk/xmlui/handle/123456789/14909
Martins J, Salgado P, Santos E, Marta M, Franca M (2015). CSF escape in an HIV-infected patient receiving antiretroviral therapy. EUROPEAN JOURNAL OF NEUROLOGY. vol. 22, 511-511.
Umaipalan A, Rackstraw S, Marta M (2015). Prevalence of neurological disease at a joint HIV neurology clinic in East London. HIV MEDICINE. vol. 16, 45-45.
Marques IB, Flanagan S, Noble H, Giovannoni G, Marta M(2015). Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse. Neurol Neuroimmunol Neuroinflamm vol. 2, (2)
10.1212/NXI.0000000000000074
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6959
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC et al.(2015). Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal vol. 21, (8) 1013-1024.
10.1177/1352458514568827
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7011
Fine D, Dattani A, Moreira I, Giovannoni G, Marta M(2015). Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?. Multiple Sclerosis and Related Disorders vol. 4, (1) 88-91.
10.1016/j.msard.2014.11.007
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D et al.(2015). No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurology: Neuroimmunology and NeuroInflammation vol. 2, (6)
10.1212/NXI.0000000000000158
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12681
Marques IB, Giovannoni G, Marta M(2014). Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. BMC Neurol vol. 14,
10.1186/s12883-014-0237-5
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11263
Castelo-Branco G, Stridh P, Guerreiro-Cacais AO, Adzemovic MZ, Falcão AM, Marta M, Berglund R, Gillett A et al.(2014). Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats. Neurobiol Dis vol. 71, 220-233.
10.1016/j.nbd.2014.08.019
https://qmro.qmul.ac.uk/xmlui/handle/123456789/14910
Schmierer K, Marta M, Turner BP, Giovannoni G (2014). THE USE OF MAGNETIC RESONANCE IMAGING (MRI) IN THE MANAGEMENT OF MULTIPLE SCLEROSIS IN THE UK. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. vol. 85,
10.1136/jnnp-2014-309236.131
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7245
Fine D, Dattani A, Moreira I, Giovannoni G, Marta M(2014). Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?. Multiple Sclerosis and Related Disorders
10.1016/j.msard.2014.11.007
Monica Marta IM(2014). New and Old Concepts and Strategies for Progressive Multifocal Leukoencephalopathy. Journal of Multiple Sclerosis vol. 02, (01)
10.4172/2376-0389-1000126
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11259
Flytzani S, Stridh P, Guerreiro-Cacais AO, Marta M, Hedreul MT, Jagodic M, Olsson T(2013). Anti-MOG antibodies are under polygenic regulation with the most significant control coming from the C-type lectin-like gene locus. Genes Immun vol. 14, (7) 409-419.
10.1038/gene.2013.33
Gnanapavan S, Grant D, Morant S, Furby J, Hayton T, Teunissen CE, Leoni V, Marta M et al.(2013). Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS - Neurofilament as a Surrogate of Disease Progression. PLOS ONE vol. 8, (8) Article ARTN e70019,
10.1371/journal.pone.0070019
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11260
CALADO MARTA MS, Papachatzaki MM(2012). Treatment issues in multiple sclerosis. Multiple Sclerosis Visual Guide for Clinicians, Editors: Giovannoni, G, Dobson, R, Hodder Christian Books
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11212
CALADO MARTA MS, giovannoni(2012). ‘What does it mean to have MS? - chapter. Multiple Sclerosis, Oxford University Press (United Kingdom),
Marta M, Giovannoni G(2012). Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon. CNS Neurol Disord Drug Targets vol. 11, (5) 610-623.
10.2174/187152712801661301
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15743
Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, Melamud L, Marta M et al.(2012). Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology vol. 78, (20) 1601-1607.
10.1212/WNL.0b013e31825644ff
https://qmro.qmul.ac.uk/xmlui/handle/123456789/14911
Farrell RA, Marta M, Gaeguta AJ, Souslova V, Giovannoni G, Creeke PI(2012). Development of resistance to biologic therapies with reference to IFN-β. Rheumatology (Oxford) vol. 51, (4) 590-599.
10.1093/rheumatology/ker445
Dobson R, Meier UC, Marta M, Ramagopalan S, Giovannoni G(2011). Vitamin D deficiency - do we follow our own advice?. CLINICAL MEDICINE vol. 11, (6) 521-523.
10.7861/clinmedicine.11-6-521
Maghzi A-H, Marta M, Bosca I, Etemadifar M, Dobson R, Maggiore C, Giovannoni G, Meier U-C(2011). Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?. Pathophysiology vol. 18, (1) 13-20.
10.1016/j.pathophys.2010.04.003
Maghzi AH, Marta M, Bosca I, Savoj MR, Etemadifar M, Giovannoni G, Meier UC(2011). Epstein–Barr Virus and Multiple Sclerosis: Wrong Place, Wrong Time?. Neuroinflammation, Editors: Minagar, A, Elsevier
Marta M, Santos E, Coutinho E, da Silva AM, Correia J, Vasconcelos C, Giovannoni G (2011). INCREASED SERUM IL-8 LEVELS IN BEHCET DISEASE THAN NEUROBEHCET SYNDROME. CLIN EXP RHEUMATOL. vol. 29, 173-173.
Marta M, Santos E, Coutinho E, da Silva AM, Correia J, Vasconcelos C, Giovannoni G (2011). VIRAL INFECTIONS IN NEUROBEHCET SYNDROME. CLIN EXP RHEUMATOL. vol. 29, 193-194.
Marta M (2010). Gene regulation and immune mechanisms in multiple sclerosis experimental models. Supervisors: Olsson, T, Presented at: Karolinska Institutet,
Stridh P, Thessen Hedreul M, Beyeen AD, Adzemovic MZ, Laaksonen H, Gillett A, Ockinger J, Marta M et al.(2010). Fine-mapping resolves Eae23 into two QTLs and implicates ZEB1 as a candidate gene regulating experimental neuroinflammation in rat. PLoS One vol. 5, (9)
10.1371/journal.pone.0012716
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11261
Gillett A, Marta M, Jin T, Tuncel J, Leclerc P, Nohra R, Lange S, Holmdahl R et al.(2010). TNF production in macrophages is genetically determined and regulates inflammatory disease in rats. J Immunol vol. 185, (1) 442-450.
10.4049/jimmunol.0904101
Marta M, Stridh P, Becanovic K, Gillett A, Ockinger J, Lorentzen JC, Jagodic M, Olsson T(2010). Multiple loci comprising immune-related genes regulate experimental neuroinflammation. Genes Immun vol. 11, (1) 21-36.
10.1038/gene.2009.62
Maghzi AH, Meier U, Holden D, Marta M, Kantor A, Waubant E, Giovannoni G, Goelz S (2009). Natural killer cell status in multiple sclerosis and its association with interferon beta-1a treatment. MULTIPLE SCLEROSIS. vol. 15, S73-S73.
Marta M(2009). Toll-like receptors in multiple sclerosis mouse experimental models. Ann N Y Acad Sci vol. 1173, 458-462.
10.1111/j.1749-6632.2009.04849.x
Marta M, Meier UC, Lobell A(2009). Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmun Rev vol. 8, (6) 506-509.
10.1016/j.autrev.2009.01.006
Huberle A, Beyeen AD, Ockinger J, Ayturan M, Jagodic M, de Graaf KL, Fissolo N, Marta M et al.(2009). Advanced Intercross Line Mapping Suggests That Ncf1 (Ean6) Regulates Severity in an Animal Model of Guillain-Barre Syndrome. J IMMUNOL vol. 182, (7) 4432-4438.
10.4049/jimmunol.0803847
Gillett AM, Marta M, Olsson T, Harris R, Jagodic M(2009). Genetic potential of macrophage TNF production regulates immune mediated diseases. JOURNAL OF IMMUNOLOGY vol. 182,
Maggiore C, Meier UC, Marta M, Nissim A, Giovannoni G (2009). B Cells and EBV Infection in People with MS. NEUROLOGY. vol. 72, A37-A37.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7010
Guo JP, Backdahl L, Marta M, Mathsson L, Ronnelid J, Lorentzen JC(2008). Profound and paradoxical impact on arthritis and autoimmunity of the rat antigen-presenting lectin-like receptor complex. ARTHRITIS RHEUM vol. 58, (5) 1343-1353.
10.1002/art.23434
Marta M, Andersson A, Isaksson M, Kampe O, Lobell A(2008). Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. EUR J IMMUNOL vol. 38, (2) 565-575.
10.1002/eji.200737187
Silva AM, Pereira C, Bettencourt A, Carvalho C, Couto AR, Leite MI, Marta M, Freijo M et al.(2007). The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population. J NEUROL SCI vol. 258, (1-2) 69-74.
10.1016/j.jns.2007.02.033
Maia LF, Marta M, Lopes V, Rocha N, Lopes C, Martins-da-Silva A, Monteiro L(2006). Hypersomnia in Whipple disease - Case report. ARQ NEURO-PSIQUIAT vol. 64, (3B) 865-868.
10.1590/s0004-282x2006000500030
Marta M, Andersson A, Isaksson M, Lobell A (2006). Unexpected regulatory roles of TLR4 and TLR9 in an animal model for multiple sclerosis. JOURNAL OF NEUROIMMUNOLOGY. vol. 178, 105-105.
Sheng JR, Jagodic M, Dahlman I, Becanovic K, Nohra R, Marta M, Iacobaeus E, Olsson T et al.(2005). Eae19, a new locus on rat chromosome 15 regulating experimental autoimmune encephalomyelitis. GENETICS vol. 170, (1) 283-289.
10.1534/genetics.104.035261
Roxburgh RHSR, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C et al.(2005). Multiple sclerosis severity score - Using disability and disease duration to rate disease severity. NEUROLOGY vol. 64, (7) 1144-1151.
10.1212/01.WNL.0000156155.19270.F8
Jagodic M, Marta M, Becanovic K, Sheng JR, Nohra R, Olsson T, Lorentzen JC(2005). Resolution of a 16.8-mb autoimmunity-regulating rat chromosome 4 region into multiple encephalomyrelitis quantitative trait loci and evidence for epistasis. J IMMUNOL vol. 174, (2) 918-924.
10.4049/jimmunol.174.2.918
Olsson T, Wallstrom E, Jagodic M, Becanovic K, Marta M, Lidman O, Swanberg M, Piehl F (2004). High resolution gene mapping of rat neuroinflammation. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 8-8.
Marta M, Jagodic M, Olsson T, Lorentzen JC (2004). High-resolution mapping of quantitative trait loci that influence an experimental model for multiple sclerosis in the rat. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 23-23.
Sheng JR, Jagodic M, Dahlman I, Becanovic K, Nohra R, Marta M, Iacobaeus E, Olsson T et al. (2004). Specially designed congenic rats on chromosome 15 provide a powerful tools for unravelling the genetic and immunological factors involved in the development of MOG-induced EAE. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 23-23.
Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J et al. (2004). TIM-3 and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. JOURNAL OF NEUROIMMUNOLOGY. vol. 154, 104-104.
Khademi M, Illés Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J et al.(2004). T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol vol. 172, (11) 7169-7176.
10.4049/jimmunol.172.11.7169
Silva BM, Thorlacius T, Benediktsson K, Pereira C, Fossdal R, Jonsson HH, Silva A, Leite I et al.(2003). A whole genome association study in multiple sclerosis patients from north Portugal. J NEUROIMMUNOL vol. 143, (1-2) 116-119.
10.1016/j.jneuroim.2003.08.024
Sousa A, Silva AM, Marta M, Sequeiros J, Coelho T(2001). Familial amyloid neuropathy (FAP Met30) in Portugal: a combined use of family studies and a 60 years' register in the assessment of anticipation of age-at-onset and of the evolutionary dynamics of the gene. AM J HUM GENET vol. 69, (4) 422-422.
Return to top